Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

About this update from Mirum Pharmaceuticals, Inc.

[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2023 financial results on Thursday, August 3, 2023. Mirum will also host a conference call to discuss the second quarter 2023 financial results and recent corporate progress.\n\n\nConference call details:\nThursday, August 3, 2023\n4:30 p.m. ET / 1:30 p.m. PT\n\n\nDial-in:\nU.S./Toll-Free: +1 833 470 1428\nInternational: + 1 404 975 4839\nPasscode: 969043\n\n\nYou may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.\n\n\nAbout Mirum Pharmaceuticals, Inc.\n\n\nLIVMARLI® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and the only approved medication by the U.S. Food and Drug Administration for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) three months of age and older.\n\n\nLIVMARLI is also the only approved IBAT inhibitor approved by the European Commission for the treatment of cholestatic pruritus in patients with ALGS two months and older, and by Health Canada for the treatment of cholestatic pruritus in ALGS. For more information for U.S. residents, please visit LIVMARLI.com.\n\n\nMirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older, and in Europe, in PFIC for patients two months of age and older.\n\n\nLIVMARLI is currently being evaluated in late-stage clinical studies in other rare cholestatic liver diseases including biliary atresia. LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.\n\n\nFollow Mirum on Twitter, Facebook, LinkedIn and Instagram.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230727925918/en/\n\nInvestor Contacts:\nAndrew McKibben\[email protected]\n\n\nSam Martin\nArgot Partners\[email protected]\n\n\nMedia Contact:\nErin Murphy\[email protected]\n\n\nSource: Mirum Pharmaceuticals, Inc.","length":5758,"tagName":"div"}]

More updates from Mirum Pharmaceuticals, Inc.